News Releases
Oncolytics Biotech Inc. to Present at the Rodman & Renshaw TechVest 7th Annual Healthcare Conference

CALGARY, Alberta, --- November 3, 2005 – Mr. Doug Ball, Chief Financial Officer of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview at the Rodman & Renshaw TechVest 7th Annual Healthcare Conference on Tuesday, November 8 at 3:30 P.M. (ET) to analysts, portfolio managers, investment bankers and other financial professionals. The event will be held at the New York Palace Hotel in New York City from November 7-9, 2005.

A live audio webcast of the presentation will be available at: http://www.rodmanandrenshaw.com/rodman.asp?link=Conferences7/ConferenceWebcasters&bgcolor=wht
or on the company’s website. It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.

An audio replay will be accessible immediately following the presentation and will be available until November 17, 2005 at www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of REOLYSIN®, its proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics’ researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells that are derived from many types of cancer including breast, prostate, pancreatic, bladder and brain tumours, and have also demonstrated successful cancer treatment results in a number of animal models. Phase I clinical trial results have indicated that REOLYSIN® was well tolerated and that the reovirus demonstrated activity in tumours injected
with REOLYSIN®.

The presentation and webcast times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company’s control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN® as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward looking statements. The Company does not undertake to update these forward looking statements.